NCT06465108已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study)
MBX Biosciences33 个研究点 分布在 3 个国家目标入组 64 人开始时间: 2024年8月8日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 64
- 试验地点
- 33
- 主要终点
- To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15
研究概览
简要总结
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
详细描述
This study is to investigate the safety, pharmacokinetics, and efficacy of MBX 2109 administered once weekly to patients with hypoparathyroidism. Given MBX 2109 is intended as a parathyroid hormone (PTH) replacement hormone to demonstrate that MBX 2109 can maintain serum calcium within a normal range without the need for active vitamin D and therapeutic calcium supplements.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is an adult ≥18 years of age at the time of the Screening visit.
- •a. If ≤25 years of age, radiological evidence of epiphyseal closure based on X-ray of non-dominant wrist and hand
- •Has a diagnosis of one of the following types of hypoparathyroidism for at least 26 weeks prior to the Screening visit:
- •Postsurgical chronic hypoparathyroidism
- •Idiopathic hypoparathyroidism
- •Autoimmune hypoparathyroidism (e.g., isolated autoimmune hypoparathyroidism; stable, well-managed patients with autoimmune polyglandular syndrome type 1/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy without current or past malabsorption at the discretion of the principal investigator [PI])
- •On a dose for at least 4 weeks prior to the Screening visit of the following:
- •Calcitriol ≥0.5 µg per day or alfacalcidol ≥1 ug per day (active vitamin D)
- •Elemental calcium (citrate or carbonate) supplement ≥800 mg per day
- •a) If the patient had a history of hypercalcemia on the above active vitamin D and/or calcium doses, the patient may be eligible to participate in the study on lower doses of calcitriol, alfacalcidol and/or elemental calcium with approval of the medical monitor
- •At the Screening visit or at completion of the Optimization Period, the following serum analytes must be within the following ranges:
- •AdjCa: 8.2 to 10.6 mg/dL (2.05 to 2.65 mmol/L), inclusive, targeting the lower half of the reference range
- •25 (OH)D: 30 to 64 ng/mL (75 to 160 nmol/L), inclusive
- •Magnesium: within the normal range of 1.8 to 2.6 mg/dL (0.65 to 1.05 mmol/L; 1.3 mEq/L to 2.1 mEq/L), inclusive; if the patient had a history of not being successful in maintaining serum magnesium within the normal reference range, a level slightly below the normal range (≥1.3 mg/dL [≥0.53 mmol/L]) may be acceptable with approval by the medical monitor 1.3 mEq/L to 2.1 mEq/L), inclusive
- •Has an estimated glomerular filtration rate >60 mL/min/1.73 m2, as estimated using the Chronic Kidney Disease Epidemiology Collaboration equation, at the Screening visit.
- •Has thyroid-stimulating hormone (TSH) within normal laboratory limits prior to randomization. If patient is on thyroid medication, the dose should be stable for at least 4 weeks. If TSH is not within normal limits at screening, the dose of thyroid medication may be adjusted and TSH repeated in 4 weeks. If receiving suppressive therapy for a history of (differentiated) thyroid cancer, TSH level must be ≥0.2 mIU/L.
- •Can comprehend and is willing to sign an informed consent form (ICF) and to abide by the study restrictions, study visits, and procedures.
排除标准
- •Has a known history of pseudohypoparathyroidism (impaired responsiveness to PTH, which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia).
- •Has any disease (other than hypoparathyroidism) that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels (e.g., disorders of the calcium sensing receptor [e.g., autosomal dominant hypocalcemia type 1] are exclusionary).
- •Use any of the following therapies:
- •Loop diuretics, thiazide diuretics, phosphate binders (other than calcium carbonate or citrate), digoxin, lithium, methotrexate, raloxifene hydrocholoride, or acute systemic corticosteroids within 4 weeks prior to the Screening Visit;
- •Chronic systemic corticosteroid use is allowed if the dose has been stable for 4 weeks prior to Screening visit
- •PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 4 weeks of the Screening visit;
- •Oral or intravenous bisphosphonates, denosumab, or romosozumab-aqqg within 18 months of the Screening visit; or
- •Other drugs known to influence calcium and bone metabolism such as calcitonin, fluoride tablets (>0.5 mg per day), strontium or cinacalcet hydrochloride within 3 months of the Screening visit.
- •Had a non-hypocalcemic seizure within 6 months of the Screening visit. Note: a history of seizures that occur in the setting of hypocalcemia is not exclusionary
- •Is at an increased risk for osteosarcoma (e.g., Paget's disease, prior history of substantial external beam or implant radiation therapy involving the skeleton, unexplained elevations of alkaline phosphatase)
- •Is affected by active or uncontrolled disease processes that may adversely affect gastrointestinal absorption at the discretion of the PI.
- •Has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than differentiated thyroid cancer, basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 2 years from the Screening visit.
- •Has any clinically significant cardiovascular disease within 6 months prior to the Screening visit such as symptomatic heart failure, an acute coronary syndrome, uncontrolled arrhythmia, or cerebrovascular accident.
- •Has a clinically significant abnormal 12-lead ECG in the opinion of the investigator at the Screening visit suggestive of underlying cardiac disease.
- •Has a seated systolic blood pressure <100 mmHg or >165 mmHg and/or diastolic blood pressure >100 mmHg at the Screening visit. If outside this range, measurement can be repeated on another day for eligibility purposes within the Screening Period. If on medications for hypertension, the doses should be stable for 4 weeks prior to the Screening visit.
- •Has a history of symptomatic nephrolithiasis within 3 months of the Screening visit.
- •Has an episode of acute gout within 2 months of the Screening visit.
- •Has any major surgery performed within the 6 months prior to the Screening visit or plans to have surgical procedures that might interfere with the patient's ability to complete the study.
- •Is pregnant, lactating or a woman of childbearing potential (WOCBP) who plans to conceive during the study.
- •WOCBP must use at least 2 highly effective methods of contraception throughout the study and for 6 weeks following administration of the last dose of study drug.
- •A heterosexually active male patient and his female partner(s) of childbearing potential must agree to use 2 effective birth control methods for the duration of the study and for 90 days after the last dose of study drug. A male patient must agree to refrain from sperm donation from the date of screening until 90 days after his last dose of study drug.
- •Has any disease or condition that, in the opinion of the investigator, may make the patient unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
- •Has a known allergy or sensitivity to PTH or any of the excipients used in MBX
- •Has a diagnosis of drug or alcohol dependence within 12 months prior to the Screening visit.
- •Has participated in any other interventional trial in which the patient received an investigational drug within 2 months or within 5 half-lives of the investigational drug (whichever is the longest) prior to the Screening visit.
- •Has any other reason that, in the opinion of the investigator, would prevent the patient from completing participation or following the study schedule.
研究组 & 干预措施
Starting dose of 400 µg once-weekly by subcutaneous injection
Experimental
干预措施: MBX 2109 (Drug)
Starting dose of 600 µg once-weekly by subcutaneous injection
Experimental
干预措施: MBX 2109 (Drug)
Starting dose of 800 µg once-weekly by subcutaneous injection
Experimental
干预措施: MBX 2109 (Drug)
Placebo - once-weekly by subcutaneous injection
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15
时间窗: Week 12
Proportion of patients pooled across MBX 2109 doses meeting the composite criteria at week 12/Visit 15 * Independence from active vitamin D supplements * Oral elemental calcium doses of ≤600 mg/day * Serum albumin-adjusted calcium (AdjCa) values of 8.2 to 10.6 mg/dL
次要结局
未报告次要终点
研究者
研究点 (33)
Loading locations...
相似试验
已完成
2 期
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout PatientsGoutNCT01399008CymaBay Therapeutics, Inc.100
已完成
2 期
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideMalignant MelanomaNCT00135408Bristol-Myers Squibb115
已完成
2 期
A Study of MDX-1100 in Subjects With Active Ulcerative ColitisUlcerative ColitisNCT00656890Bristol-Myers Squibb110
已完成
2 期
Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation BurdenAtrial FibrillationNCT01356914Bristol-Myers Squibb20
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy TrialNon-obstructive Hypertrophic CardiomyopathyNCT04826185Imbria Pharmaceuticals, Inc.67